These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28609161)

  • 21. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
    Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
    J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
    Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
    J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
    Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
    J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.
    Khandpur S; Sharma VK
    Clin Exp Dermatol; 2011 Aug; 36(6):613-6. PubMed ID: 21507036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.
    Menter A
    Cutis; 2012 Feb; 89(2):89-94. PubMed ID: 22474733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
    Brodell R; Preston N
    J Drugs Dermatol; 2012 Dec; 11(12):1455-9. PubMed ID: 23377516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
    Reygagne P; Mrowietz U; Decroix J; de Waard-van der Spek FB; Acebes LO; Figueiredo A; Caputo R; Poncet M; Arsonnaud S
    J Dermatolog Treat; 2005 Feb; 16(1):31-6. PubMed ID: 15897165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.
    Poulin Y; Papp K; Bissonnette R; Guenther L; Tan J; Lynde C; Kerrouche N; Villemagne H;
    Cutis; 2010 Jan; 85(1):43-50. PubMed ID: 20184211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clobetasol propionate for psoriasis: are ointments really more potent?
    Warino L; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.
    Tan J; Thomas R; Wang B; Gratton D; Vender R; Kerrouche N; Villemagne H;
    Cutis; 2009 Mar; 83(3):157-64. PubMed ID: 19363909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
    Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clobetasol propionate foam in the treatment of psoriasis.
    Reid DC; Kimball AB
    Expert Opin Pharmacother; 2005 Aug; 6(10):1735-40. PubMed ID: 16086659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
    Hudson CP; Kempers S; Menter A; Papp K; Smith S; Sofen H; Colón LE; Johnson LA; Gottschalk R
    Cutis; 2011 Oct; 88(4):201-7. PubMed ID: 22106730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.
    Menter A
    Cutis; 2007 Nov; 80(5 Suppl):12-9. PubMed ID: 18154219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.